Funding of US biomedical research, 2003-2008
- PMID: 20068207
- PMCID: PMC3118092
- DOI: 10.1001/jama.2009.1987
Funding of US biomedical research, 2003-2008
Abstract
Context: With the exception of the American Recovery and Reinvestment Act, funding support for biomedical research in the United States has slowed after a decade of doubling. However, the extent and scope of slowing are largely unknown.
Objective: To quantify funding of biomedical research in the United States from 2003 to 2008.
Design: Publicly available data were used to quantify funding from government (federal, state, and local), private, and industry sources. Regression models were used to compare financial trends between 1994-2003 and 2003-2007. The numbers of new drug and device approvals by the US Food and Drug Administration over the same period were also evaluated.
Main outcome measures: Funding and growth rates by source; numbers of US Food and Drug Administration approvals.
Results: Biomedical research funding increased from $75.5 billion in 2003 to $101.1 billion in 2007. In 2008, funding from the National Institutes of Health and industry totaled $88.8 billion. In 2007, funding from these sources, adjusted for inflation, was $90.2 billion. Adjusted for inflation, funding from 2003 to 2007 increased by 14%, for a compound annual growth rate of 3.4%. By comparison, funding from 1994 to 2003 increased at an annual rate of 7.8% (P < .001). In 2007, industry (58%) was the largest funder, followed by the federal government (33%). Modest increase in funding was not accompanied by an increase in approvals for drugs or devices. In 2007, the United States spent an estimated 4.5% of its total health expenditures on biomedical research and 0.1% on health services research.
Conclusion: After a decade of doubling, the rate of increase in biomedical research funding slowed from 2003 to 2007, and after adjustment for inflation, the absolute level of funding from the National Institutes of Health and industry appears to have decreased by 2% in 2008.
Conflict of interest statement
Figures
Comment in
-
Insights from trends in biomedical research funding.JAMA. 2010 Jan 13;303(2):170-1. doi: 10.1001/jama.2009.1992. JAMA. 2010. PMID: 20068214 No abstract available.
Similar articles
-
The anatomy of medical research: US and international comparisons.JAMA. 2015 Jan 13;313(2):174-89. doi: 10.1001/jama.2014.15939. JAMA. 2015. PMID: 25585329
-
Insights from trends in biomedical research funding.JAMA. 2010 Jan 13;303(2):170-1. doi: 10.1001/jama.2009.1992. JAMA. 2010. PMID: 20068214 No abstract available.
-
Financial anatomy of neuroscience research.Ann Neurol. 2006 Dec;60(6):652-9. doi: 10.1002/ana.21047. Ann Neurol. 2006. PMID: 17192926 Review.
-
Financing of U.S. biomedical research and new drug approvals across therapeutic areas.PLoS One. 2009 Sep 11;4(9):e7015. doi: 10.1371/journal.pone.0007015. PLoS One. 2009. PMID: 19750225 Free PMC article.
-
Federal funding for aging education and research: a decade analysis.Gerontologist. 1989 Oct;29(5):606-14. doi: 10.1093/geront/29.5.606. Gerontologist. 1989. PMID: 2689294 Review.
Cited by
-
Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.Public Health Ethics. 2024 Mar 1;17(1-2):24-39. doi: 10.1093/phe/phae002. eCollection 2024 Apr-Jul. Public Health Ethics. 2024. PMID: 39415824 Free PMC article.
-
Precision medicine in AML: overcoming resistance.Int J Hematol. 2024 Oct;120(4):439-454. doi: 10.1007/s12185-024-03827-8. Epub 2024 Aug 1. Int J Hematol. 2024. PMID: 39085680 Review.
-
The landscape of biomedical research funding in Brazil: a current overview.Int Braz J Urol. 2024 Mar-Apr;50(2):209-222. doi: 10.1590/S1677-5538.IBJU.2024.9905. Int Braz J Urol. 2024. PMID: 38386791 Free PMC article. Review.
-
Inflation-adjusted medicare physician reimbursement for adult spinal deformity surgery substantially declined from 2002 to 2020.Spine Deform. 2024 Mar;12(2):263-270. doi: 10.1007/s43390-023-00779-7. Epub 2023 Nov 30. Spine Deform. 2024. PMID: 38036867 Review.
-
Has pharmaceutical innovation reduced the average cost of U.S. health care episodes?Int J Health Econ Manag. 2024 Mar;24(1):1-31. doi: 10.1007/s10754-023-09363-y. Epub 2023 Nov 8. Int J Health Econ Manag. 2024. PMID: 37940731
References
-
- Moses H, III, Dorsey ER, Matheson DH, Thier SO. Financial Anatomy of Biomedical Research. JAMA. 2005;294:1333–1342. - PubMed
-
- Biomedical Research and Development Price Index (BRDPI) Bethesda, Md: Office of Science and Policy Planning; 2009. [Accessed April 13, 2009]. Available at: http://officeofbudget.od.nih.gov/gbiPriceIndexes.html.
-
- BRDPI: FY 2008 Update and Projections for FY 2009–2014. National Institute of Health, Office of Budget; [Accessed November 23, 2009.]. Available at: http://officeofbudget.od.nih.gov/pdfs/FY09/BRDPI_Proj_Feb_2009_final.pdf.
-
- National Science Foundation, Division of Science Resource Statistics. [Accessed April 13, 2009.];Federal Funds for Research and Development: Fiscal Years 2005–07. Publication No. 09–300. Available at: http://www.nsf.gov/statistics/nsf09300/pdf/nsf09300.pdf.
-
- Funding: Glossary & Acronym List. US Department of Health & Human Services; [Accessed November 23, 2009.]. Available at: http://grants.nih.gov/Grants/glossary.htm.
